Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- aprotinin
- Kabikinase (streptokinase)
Interactions between your drugs
streptokinase aprotinin
Applies to: Kabikinase (streptokinase), aprotinin
MONITOR: Coadministration of an antifibrinolytic agent (e.g., aminocaproic acid, tranexamic acid, aprotinin) in combination with a tissue plasminogen activator (t-PA) may reduce the therapeutic effects of both drugs due to opposing pharmacodynamic actions. Aminocaproic acid and tranexamic acid are competitive inhibitors of plasminogen activation. At high concentrations they can also directly inhibit plasmin, which is needed for the degradation of fibrin and thrombolysis. Aprotinin is a broad-spectrum protease inhibitor that inhibits plasmin. It is known to have antifibrinolytic activity and may interact with t-PAs in a similar fashion.
MANAGEMENT: No specific intervention is warranted, but clinicians should be alert to the potential for diminished therapeutic efficacy if a tissue plasminogen activator is administered to a patient who has been treated with an antifibrinolytic agent, and vice versa.
References (4)
- (2001) "Product Information. Trasylol (aprotinin)." Bayer
- (2001) "Product Information. Amicar (aminocaproic acid)." Immunex Corporation
- (2001) "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn
- (2022) "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Zoladex
Zoladex (goserelin) is used to treat endometriosis and breast cancer in women and prostate cancer ...
Lysteda
Lysteda (tranexamic acid) is used to treat heavy menstrual bleeding. Includes Lysteda side effects ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Cyklokapron
Cyklokapron is used for bleeding disorder, factor ix deficiency, hemophilia a
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Dexamethasone Intensol
Dexamethasone Intensol is used for addison's disease, adrenal insufficiency, adrenocortical ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Promacta
Promacta is used to prevent bleeding episodes in patients with chronic immune (idiopathic) ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.